Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes

Tumor heterogeneity has been identified at various -omic levels. The tumor genome, transcriptome, proteome, and phenome can vary widely across cells in patient tumors and are influenced by tumor cell interactions with heterogeneous physical conditions and cellular components of the tumor microenviro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular medicine (Berlin, Germany) Germany), 2017-11, Vol.95 (11), p.1167-1178
Main Authors: McQuerry, Jasmine A., Chang, Jeffrey T., Bowtell, David D. L., Cohen, Adam, Bild, Andrea H.
Format: Article
Language:English
Subjects:
Animals
Biomedical and Life Sciences
Biomedicine
Cell interactions
Energy Metabolism
Gene expression
Genetic Heterogeneity
Genomes
Heterogeneity
Human Genetics
Humans
Internal Medicine
Molecular Medicine
Molecular Targeted Therapy
Neoplasms - etiology
Neoplasms - metabolism
Neoplasms - pathology
Neoplasms - therapy
Phenotype
Proteomes
Recurrence
Review
Tumor Microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor heterogeneity has been identified at various -omic levels. The tumor genome, transcriptome, proteome, and phenome can vary widely across cells in patient tumors and are influenced by tumor cell interactions with heterogeneous physical conditions and cellular components of the tumor microenvironment. Here, we explore the concept that while variation exists at multiple -omic levels, changes at each of these levels converge on the same pathways and lead to convergent phenotypes in tumors that can provide common drug targets. These phenotypes include cellular growth and proliferation, sustained oncogenic signaling, and immune avoidance, among others. Tumor heterogeneity complicates treatment of patient cancers as it leads to varied response to therapies. Identification of convergent cellular phenotypes arising in patient cancers and targeted therapies that reverse them has the potential to transform the way clinicians treat these cancers and to improve patient outcome.
ISSN:0946-2716
1432-1440
DOI:10.1007/s00109-017-1587-4